You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 1 Issues Articles
Popular Type 1 Issues Articles
Highly Recommended Type 1 Issues Articles
Send a link to this page to your friends and colleagues.
On January 15, 2007, GW Pharmaceuticals reported results achieved by Sativex, its mouth spray made from pot, in a multi-center, double-blind, randomized, placebo-controlled study of nearly 300 patients with diabetic neuropathic pain.
The study participants were already taking the best available pain treatments, without relief. Even among those difficult patients, 30 percent showed an improvement in pain, and one third of those showed an over 50 percent improvement in pain. This is one of the highest levels of positive response seen in the published literature.
Unfortunately, the study results were somewhat confounded by the fact that the people who were spraying the placebo started feeling pretty good as well. For that reason, although Sativex beat the placebo in all respects, the difference between Sativex and the placebo did not reach statistical significance.
Sativex, which is refined from pot grown in heavily fortified greenhouses, is available only in Canada at the moment, for use with multiple sclerosis. GW Pharmaceuticals is working toward approvals for other pain-relieving applications, including diabetic neuropathic pain.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.